Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Most Picturesque Biopharma Location? | Main | Well, Okay: The Ugliest Biopharma Sites? »

October 12, 2010

Exelixis Grabs A Life Preserver

Email This Entry

Posted by Derek

I was talking with some folks about this just last night - looks like Exelixis has rounded up some more money by signing a revised deal with BMS. They've been having a rough time out there recently, so I'm glad that there's a lifeline available. More on this as things become clearer. . .

Comments (5) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. AlchemistOrganique on October 12, 2010 2:10 PM writes...

Just read the C&E News article online. OMG, is that Tarceva drawn on the hood sash? I'm assuming that was drawn for the publicity shot rather than representative of a current analog project!

Permalink to Comment

2. watcher on October 12, 2010 7:24 PM writes...

I don't know why you are feeling so generous and sympathetic for the company...certainly it's always bad for individuals who get caught at no fault of their own.

Yet, Excelixis make promises, promises, promises yet don't come close to delivering uniqueness or value. They've taken millions in deal funding, not to return much to the partner companies. They keep pushing the same compounds, knocking on door after door, one company to another. You'd think after a while they'd get the message that the compounds simply don't look good enough to take them further.

The strongest survive; the weaker wither away (well normally, but not always).

Permalink to Comment

3. Osaka on October 13, 2010 5:11 AM writes...

In almost any non-greedy selection or optimization algorithm, certain non-optimal candidates must be maintained to prevent stagnation. You can set the bar arbitrarily high for what can or cannot be used, sure, but you get an exponential back off on actual results. It actually makes more sense to have variety than to have all the strongest set, which is exactly how natural selection works.

So your statement that the "strongest survive" is very suspect; the strongest are only strongest today, and even then it's hard to tell exactly what 'strongest" means. If the population as a whole wants to remain as fit as possible, it must have variety, especially some amount of variety below the watermark.

The "weaker" do not wither away; they serve as containers for variety for when the "strong" are the "weak", ie, when times change.

Permalink to Comment

4. Anonymous on October 13, 2010 7:26 AM writes...

Just heard King Pharma has been 'assimilated'. Yet another one bites the dust

Permalink to Comment

5. Resistancei is futile! on October 13, 2010 8:33 AM writes...

Nooo!!! The Pfi-Borg strikes again!

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern